In the News
Jan 01, 2011
The pace of change we've seen in the past five years in oncology will be insignificant in comparison with what's coming around the bend. As oncology practices will be pinched tighter than ever, they will need fulltime resources dedicated to chasing pre-authorizations and reimbursements. Moreover, cost considerations will increasingly factor heavily into patients' treatment decisions, and pharmaceutical R&D efforts will reach for the promise of personal medicine by investing billions of dollars in drugs that may only serve a small patient population - but with potentially far better efficiacy - while ignoring latter lines of therapy where usage might be limited by clinical pathways. And, that's just scratching the surface.